Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 13, 2018. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions.
| Transaction Date | Instrument | Price per Share | Total Volume |
|---|---|---|---|
| April 12, 2018 | Ordinary Shares (25p each) | £14.3940 | 1,125 shares |
Note: The total volume of 1,125 shares is the aggregate of three separate transactions executed at the same price on the same date.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses the acquisition of shares by specific individuals.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed on the London Stock Exchange (XLON) and resulted from the re-investment of dividends paid to shareholders on April 12, 2018.
Important Facts for Investors
- Transaction Nature: All reported transactions were acquisitions of ordinary shares via dividend re-investment plans, not open market purchases or sales.
- Participants: The transactions involved Mrs. V A Whyte (Company Secretary), Mr. I W Whyte (PCA of Mrs. Whyte), and Mrs. D Connor (PCA of Mr. R G Connor, President, Global Manufacturing & Supply).
- Volume: The total number of shares acquired across all three individuals was 1,125.
- Price: All shares were acquired at a uniform price of £14.3940.